## UNITED STATES SECURITIES AND EXCHANGE COMMISSION DECEMBER 22, 2016

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## ImmunoGen, Inc.

File No. 000-17999 - CF #34379

ImmunoGen, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from Exhibits 10.2 and 10.3 to a Form 10-Q filed on November 3, 2006, as modified by the same contracts refiled with fewer

Based on representations by ImmunoGen, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit	to Form	Filed on	<b>Confidential Treatment Granted</b>
10.1	10-Q	November 4, 2016	through December 10, 2019
10.2	10-Q	November 3, 2006	through December 10, 2019
10.3	10-Q	November 3, 2006	through December 10, 2019

redactions as Exhibit 10.1 to a Form 10-Q filed on November 4, 2016.

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary